143 related articles for article (PubMed ID: 8656697)
1. P-glycoprotein expression in patients with acute leukemia-clinical relevance.
Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gieseler F; Diem H; Ledderose G; Gullis E; Sauer H; Wilmanns W
Leukemia; 1996 Jul; 10 Suppl 3():S23-S31. PubMed ID: 8656697
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
[TBL] [Abstract][Full Text] [Related]
4. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
Nuessler V; Gullis E; Pelka-Fleischer R; del Valle F; Diem H; Beyerlein S; Zwierzina H; Wilmanns W
Ann Hematol; 1997; 75(1-2):17-26. PubMed ID: 9322679
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
6. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
te Boekhorst PA; Löwenberg B; Sonneveld P
Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
[TBL] [Abstract][Full Text] [Related]
13. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
Hiddemann W; Martin WR; Sauerland CM; Heinecke A; Büchner T
Leukemia; 1990 Mar; 4(3):184-8. PubMed ID: 2314117
[TBL] [Abstract][Full Text] [Related]
14. Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease.
Nuessler V; Gieseler F; Gullis E; Pelka-Fleischer R; Stötzer O; Zwierzina H; Wilmanns W
Leukemia; 1997 Dec; 11 Suppl 5():S10-4. PubMed ID: 9436932
[TBL] [Abstract][Full Text] [Related]
15. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
16. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
[TBL] [Abstract][Full Text] [Related]
18. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gullis E; Gieseler F; Bock S; Bartl R; Petrides PE
Ann Hematol; 1994; 69 Suppl 1():S25-9. PubMed ID: 7914749
[TBL] [Abstract][Full Text] [Related]
19. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
20. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
